NASDAQ:VXRT

Vaxart Stock Predictions

Healthcare > Biotechnology

Buy VXRT

*Your capital is at risk

$0.600

-0.0049 (-0.81%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

VXRT Prediction Chart

VXRT Predictions History

Latest community submissions for VXRT.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
Lynn Ryan @LynnRyan.165207	Jun 29, 2020	Bearish	$7.49	X	—	0
JS Pro	Apr 23, 2020	$2.82 +5.22%	$2.68	X	94.78%	1
JS Pro	Apr 22, 2020	$3.24 +9.83%	$2.95	X	90.17%	0
2poJeff Pro	Apr 22, 2020	$3.05 +3.39%	$2.95	X	96.61%	1
JS Pro	Apr 6, 2020	$1.70 -1.16%	$1.72	X	98.84%	1
2poJeff Pro	Apr 6, 2020	$1.65 -4.07%	$1.72	X	95.93%	0
Gordon Meiners, III @GordonMeiners2CIII.150747	Apr 6, 2020	$1.80 +4.65%	$1.72	X	95.35%	1
Brendan.Coggins.25391	Apr 2, 2020	$1.73 +2.98%	$1.68	X	97.02%	1
JS Pro	Apr 1, 2020	$1.74 +0.58%	$1.73	X	99.42%	4
Glickman	Apr 1, 2020	Bearish	$1.73	X	—	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for VXRT with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT VAXART

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the t...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by